The patient’s breast tumour carried a PIK3CA mutation (also found in the PDX) and the patient was treated with a PI3Kα inhibitor combined with the AI letrozole in the neo-adjuvant setting (Fig. 3a). Here, PIK3CA is linked to breast neoplasm.